Everett, WA, April 18, 2013 – SNBL USA, the experts in primate research, has entered into a consulting agreement with Dr. Pritam Sahota of Global ToxPath, LLC. Sahota is a recognized industry leader in toxicologic pathology evaluations within the framework of pharmaceutical nonclinical safety assessment. This agreement allows SNBL USA to utilize Sahota’s expertise to augment its pathology services on an ongoing basis and maximize the company’s ability to provide high-quality, on-time study conduct for clients.
Prior to forming Global ToxPath in 2012, Sahota held various positions at Novartis including executive director of pathology and executive director of special preclinical safety projects. He has been responsible for Novartis’ anatomic, clinical, investigative and discovery pathology, including contracted studies, and has led special projects centered on cardiotoxicity, ocular toxicity, carcinogenicity, drug repositioning and patient centricity. Sahota’s new book “Toxicologic Pathology” was well received at the Society of Toxicology Annual Meeting this year.
“SNBL USA takes great pride in providing the best service to our clients. This collaboration with Dr. Pritam Sahota allows us to capitalize on our combined and complementary expertise,” said Dr. Stewart Jacobson, SNBL USA director of pathology services. “We are very excited to have Pritam working with us to provide additional support with client study designs and program development, peer reviews and general pathologic expertise.”
For additional information regarding SNBL’s pathology services or toxicology services in general, please contact SNBL USA at 425.322.1950 or info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL USA, Ltd. offers a unique range of safety assessment services to fulfill its commitment to help free patients from suffering. Managed and operated by a team world renowned for its wide-ranging nonhuman primate (NHP) experience and expertise, SNBL offers programs ranging from regulatory toxicology to customized study designs. SNBL’s specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity.
